NexImmune, Inc. announced that Mathias Oelke, Ph.D., has been promoted to Chief Scientific Officer. Dr. Oelke is a scientific co-founder of NexImmune and joined NexImmune in 2014.
Dr. Oelke has more than 20 years of research experience in cancer immunotherapy and has a long-standing track record of developing methods for antigen-specific stimulation of T cells for therapeutic use. Prior to his promotion, he served as Senior Vice President, Preclinical Immunotherapy and Head of Cell Biology of NexImmune since 2017.